In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and hepatocellular carcinoma. While fibroblast growth factor 21 (FGF21) analogs have ...

Although the mechanisms are not well understood, steatohepatitis modifies the response of hepatic stellate cells to injury-related cytokines so that both transcriptional and post-transcriptional ...

Steatohepatitis is an advanced stage of liver disease. While alcohol can be the main cause, it isn't always. Let's look at treatment options and more: ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their specific roles in the progression of disease remain unknown. To address this ...

Dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis in a randomized trial in China. The study included younger patients who were predominantly ...

Steatohepatitis is an advanced stage of fatty liver disease. Learn more about the main types, their symptoms and causes, and how doctors treat the condition.

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated ...

Non-alcoholic steatohepatitis: Early signs In the initial stages, patients with non-alcoholic steatohepatitis do not usually have any symptoms and it is diagnosed when an ultrasound abdomen is ...